ARTICLES

PRELIMINARY INJUNCTIONS AND DAMAGES IN THE UK
ALASDHAIR MCDONALD
Pinsent Masons, London

Some recent changes to interim injunction law in the Patent Courts have been attributed to judges with backgrounds in competition law. However, argues the author, the reasoning for these judgments is more likely based on the adequacy and quantifiability of damages and the principles for granting interim injunctions than on scepticism about monopoly rights.

PLAUSIBILITY, POST-G2/21
PAUL ENGLAND
Taylor Wessing LLP, London

Focusing on the Warner-Lambert UK Supreme Court case concerning pregabalin and the Teva v BMS case about apixaban, this article examines the role of plausibility in both sufficiency and obviousness in the UK and compares this with the G2/21 Enlarged Board case in the EPO, to see how the approach in the EPO now differs.

PRECISION TOXICOLOGY: NEW APPROACH METHODOLOGIES FOR CHEMICAL SAFETY
ALEKSANDRA CAVOKSI,JOHN K. COLBOURNE, LAURA HOLDEN AND ROBERT G. LEE
Centre for Environmental Research and Justice,
University of Birmingham, UK

The Horizon 2020 research programme included a call for projects advancing the safety assessment of chemicals without resort to animal testing. This article discusses the Precision Tox project, in particular  the work on embedded translation that examines how scientific findings from the wider research programme might be applied in the policy and law that seeks to identify and minimize hazards emanating from  chemical substances.

THE UNIFIED PATENT COURT IS HERE: HOW IS IT BEING USED?
PAUL ENGLAND
Taylor Wessing LLP, London

The Unified Patent Court has now become a reality, despite the fact that the Milan section is not yet fully operational and the number of participating states is not yet complete. In discussing the new system the author stresses that while it seems that mainstream litigators intend to use the system, the court’s case management system is in urgent need of improvement.

CASE COMMENTS

A PHASE III CLINICAL TRIAL AND DUTY OF CARE: CARDIORENTIS AG VIQVIA LTD AND IQVIA RDS INC
JOHN HULL
Visiting Professor, 
King’s College London; Consultant Impact IP

ARTICLE 3(A) OF THE SPC REGULATION (EC) NO 469/2009 IN FRANCE: HOW THE ‘AUTONOMOUS INVENTIVE STEP’ IS CONSIDERED
HERVÉ LE QUÉRÉ AND CATHERINE TOUATI
Plassereau, Paris

THE BATTERIES REGULATION ENTERS INTO FORCE: WHAT DOES THIS MEAN FOR THE MED TECH INDUSTRY?
ABIEN ROY AND ANASTASIA VERNIKOU
Hogan Lovells, Brussels

BOOK REVIEW
SUPPLEMENTARY PROTECTION CERTIFICATES FOR MEDICINAL PRODUCTS